Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
issued the following statement regarding the decision of the U.S. Court
of Appeals for the Federal Circuit. The decision validated the patent
for CUBICIN® (daptomycin for injection) that expires on June
15, 2016, but invalidated four patents with expiration dates in 2019 and
2020.
Language:
English
Contact:
MerckMedia:Lainie Keller, 908-236-5036Steve Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Cubicin MSD NYSE:MRK Source Type: news